Evidence map›Paper›PMID 28654657›Full record

ArticlePloS one2017

HEK293T cell lines defective for O-linked glycosylation.

James M Termini, Zachary A Silver, Bryony Connor, Aristotelis Antonopoulos, Stuart M Haslam, Anne Dell, Ronald C Desrosiers

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Genetic glycoengineering in mammalian cells.The Journal of biological chemistry
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

James M TerminiDepartment of Pathology, University of Miami Miller School of Medicine, Miami, Florida, United States of America.
Zachary A SilverDepartment of Pathology, University of Miami Miller School of Medicine, Miami, Florida, United States of America.
Bryony ConnorDepartment of Life Sciences, Imperial College London, London, United Kingdom.
Aristotelis AntonopoulosDepartment of Life Sciences, Imperial College London, London, United Kingdom.
Stuart M HaslamDepartment of Life Sciences, Imperial College London, London, United Kingdom.
Anne DellDepartment of Life Sciences, Imperial College London, London, United Kingdom.
Ronald C DesrosiersDepartment of Pathology, University of Miami Miller School of Medicine, Miami, Florida, United States of America.ORCID http://orcid.org/0000-0001-6851-3003

Funding

Functional Role of O-Glycosylation of HIV-1R01AI104523 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI DESROSIERS, RONALD C · 2013 to 2024
$4.1M
NIAID NIH HHS R01 AI104523Wellcome Trust
6 · The paper itself

Abstract

Here we describe derivatives of the HEK293T cell line that are defective in their ability to generate mucin-type O-linked glycosylation. Using CRISPR/Cas9 and a single-cell GFP-sorting procedure, the UDP-galactose-4-epimerase (GALE), galactokinase 1 (GALK1), and galactokinase 2 (GALK2) genes were knocked out individually and in combinations with greater than 90% of recovered clones having the desired mutations. Although HEK293T cells are tetraploid, we found this approach to be an efficient method to target and disrupt all 4 copies of the target gene. Deficient glycosylation in the GALE knockout cell line could be rescued by the addition of galactose and N-acetylgalactosamine (GalNAc) to the cell culture media. However, when key enzymes of the galactose/GalNAc salvage pathways were disrupted in tandem (GALE+GALK1 or GALE+GALK2), O-glycosylation was eliminated and could not be rescued by the addition of either galactose plus GalNAc or UDP-galactose plus UDP-GalNAc. GALK1 and GALK2 are key enzymes of the galactose/GalNAc salvage pathways. Mass spectrometry was performed on whole cell lysate of the knockout cell lines to verify the glycosylation phenotype. As expected, the GALE knockout was almost completely devoid of all O-glycosylation, with minimal glycosylation as a result of functional salvage pathways. However, the GALE+GALK1 and GALE+GALK2 knockout lines were devoid of all O-glycans. Mass spectrometry analysis revealed that the disruption of GALE, GALK1, and GALE+GALK2 had little effect on the N-glycome. But when GALE was knocked out in tandem with GALK1, N-glycans were exclusively of the high mannose type. Due to the well-characterized nature of these five knockout cell lines, they will likely prove useful for a wide variety of applications.

Indexed as

GalactokinaseGene Knockout TechniquesGlucansGlycosylationHEK293 CellsHumansMass SpectrometryUDPglucose 4-EpimeraseGalactokinaseGALK1 protein, humanGALK2 protein, humanGlucansUDPglucose 4-Epimerase

Identifiers

PMID28654657
PMCPMC5487050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.